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High fat feeding induces a variety of obese and lean phenotypes in inbred rodents. Compared to Diet Resistant (DR) rodents,
Diet Induced Obese (DIO) rodents are insulin resistant and have a reduced dopamine receptor D2 (DRD2) mediated tone. We
hypothesized that this diﬀering dopaminergic tone contributes to the distinct metabolic proﬁles of these animals. C57Bl6 mice
were classiﬁed as DIO or DR based on their weight gain during 10 weeks of high fat feeding. Subsequently DIO mice were treated
withtheDRD2 agonistbromocriptineandDR micewiththeDRD2 antagonisthaloperidolfor2weeks.Compared toDR mice,the
bodyweight of DIO mice was higher and their insulin sensitivity decreased. Haloperidol treatment reduced the voluntary activity
and energy expenditure of DR mice and induced insulin resistance in these mice. Conversely, bromocriptine treatment tended
to reduce bodyweight and voluntary activity, and reinforce insulin action in DIO mice. These results show that DRD2 activation
partly redirects high fat diet induced metabolic anomalies in obesity-prone mice. Conversely, blocking DRD2 induces an adverse
metabolic proﬁle in mice that are inherently resistant to the deleterious eﬀects of high fat food. This suggests that dopaminergic
neurotransmissionis involved in the control of metabolic phenotype.
1.Introduction
Dopamine is intimately involved in the regulation of energy
balance. Genetically engineered dopamine-deﬁcient mice
fail to initiate feeding and consequently die of starvation,
unless L-DOPA, the precursor of dopamine, is provided
daily [1]. Conversely, dopamine release in response to food
intake induces satiety and reward [2]. Thus, dopamine plays
an important dual role in the complex physiology driving
meal initiation and termination. Moreover, dopaminergic
neurotransmission profoundly aﬀects glucose and lipid
metabolism [3].
Dopamine action is mediated by 5 distinct G-protein
coupled receptor subtypes, functionally classiﬁed into 2
receptor families according to their eﬀect on target neurons.
Activation of dopamine receptor D2 (DRD2), D3, or D4,
comprising the D2 family, inhibits adenylyl cyclase. Activa-
tion of the receptors belonging to the D1 family (DRD1 and
DRD5) stimulates adenylyl cyclase [4].
Dopaminergic transmission is altered in insulin resistant
and obese animals. Basal and feeding-evoked dopamine
release is exaggerated in several nuclei of the hypothalamus
of obese Zucker rats [5–7], whereas DRD2 expression is
reduced in hypothalamic nuclei of obese animal models
[8, 9]. The number of DRD2 binding sites in the striatum of
obese humans is reduced and inversely correlated with body
mass index [10].
Modulation of DRD2 activity profoundly aﬀects energy
homeostasis inhumans andanimals. DrugsthatblockDRD2
enhance appetite and induce weight gain in animals and2 Experimental Diabetes Research
humans [11–14]. Conversely, DRD2 agonist drugs reduce
body weight, increase energy expenditure, and improve
glycemic control in obese animals and individuals [15–18].
High fat feeding induces obesity, insulin resistance, and
diabetes in rodents. However, the amount of weight gained
in response to a high fat diet varies considerably, even
among animals with a genetically identical background
[19–21]. Indeed, diet sensitive (diet induced obese, DIO)
rodents display several alterations in pathways regulating
energy homeostasis compared to diet resistant (DR) rodents
[21, 22], and DIO and DR rodents diﬀer with respect to
various components of their dopaminergic system, even
before the onset of obesity [23, 24]. In particular, DIO
mice and rats are characterized by an increased expression
of dopamine transporter and reduced DRD2 expression
[23]. In view of the evidence summarized above, altered
DRD2-mediated neurotransmission could contribute to the
metabolic phenotype of these animals. We hypothesized that
modulation of dopaminergic transmission in DIO and DR
mice with DRD2 agonist or antagonist drugs would redirect
the metabolic phenotypes of these mice. We particularly
postulated that stimulation of DRD2 would ameliorate
insulin resistance of DIO C57Bl6 mice, whereas DRD2
antagonism would induce insulin resistance in DR animals
of the same strain. To address this hypothesis, DIO and
DR mice were treated with bromocriptine, a DRD2 agonist,
or haloperidol, a DRD2 antagonist, respectively. After 1
week of treatment, energy metabolism was measured in
a Comprehensive Laboratory Animal Monitoring System,
and after 2 weeks a hyperinsulinemic euglycemic clamp was
performed to quantify insulin action, in particular, with
respect to its propensity to inhibit lipolysis.
2.ExperimentalProcedure
2.1. Animals. Seventy-two male C57Bl6Jico mice, 11 or 12
weeksold,(CharlesRiver,Maastricht, TheNetherlands)were
housed in a temperature- and humidity-controlled room on
a 12-h light-dark cycle with free access to food and water,
unless mentioned otherwise. All animal experiments were
performed in accordance with the principles of laboratory
animal care and regulations of Dutch law on animal welfare,
and the experimental protocol was approved by the Animal
Ethics Committee of the Leiden University Medical Center.
2.2. Experimental Design. All mice were maintained on a
h i g hf a td i e t( 4 5e n e r g y %o ff a td e r i v e df r o mp a l mo i l ,
35 energy% of carbohydrate, and 20 energy% of protein—
Research Diet Services, Wijk bij Duurstede, The Nether-
lands). After 10 weeks of high fat feeding, the 24 mice with
the highest weight gain were classiﬁed as DIO mice and the
24 mice with the lowest weight gain were classiﬁed as DR
mice. The 24 mice with intermediate weight gain were not
further used in this study.
DIO and DR mice were randomly divided into a placebo
and treatment group. DR treated mice received haloperidol
(1mg/kg/day), DIO treated mice received bromocriptine
(10mg/kg/day), and DIO and DR placebo mice received
placebo treatment. Subcutaneous implantable haloperidol,
bromocriptine, and placebo pellets (Innovative Research of
America, Florida, USA), ensuring continuous release of the
medication were used to treat mice. Pellets were implanted
under isoﬂurane anesthesia. Mice were treated for 2 weeks,
meanwhile maintained on the high fat diet.
2.3.MeasurementofEnergyMetabolism. Mice were subjected
to indirect calorimetric measurements for a period of 3
consecutive days using a Comprehensive Laboratory Animal
Monitoring System (CLAMS; Columbus Instruments, Ohio,
USA). Due to a limited number of cages, eight mice per
group were measured. Mice were allowed to acclimatize to
the cages for a period of 14 hours prior to the start of the
experiment. Measurements started at 7:00 am and continued
for 72 hours. The CLAMS system enables real-time continu-
ous monitoring of food intake, drinking behavior, activity,
and metabolic gas exchange. Oxygen consumption (VO2)
and carbon dioxide productionrates (VCO2) were measured
at 7 minute intervals. The respiratory exchange rate (RER),
as a measure for metabolic substrate choice, was calculated
using the following formula:
RER =
VCO2
VO2
. (1)
Carbohydrate and fat oxidation rates were calculated
from VO2 and VCO2 using the following formulas [25]:
Carbohydrate oxidation(kcal/h) =
((4.585 ∗ VCO2) − (3.226 ∗ VO2)) ∗ 4
1000
,
Fat oxidation (kcal/h) =
((1.695 ∗ VO2) − (1.701 ∗ VCO2)) ∗ 9
1000
.
(2)
VO2 and VCO2 are in mL/h.
Total energy expenditure was calculated as the sum of
carbohydrate and fat oxidation. Activity was monitored by
infrared beam breaks across the x-a n dy-axis. All energy
metabolism data was calculated separately for day and night
time.
2.4. DEXAScan. Body composition was measured by dual-
energy X-ray absorptiometry (DEXA) using the Norland
pDEXA Sabre X-Ray Bone Densitometer (Norland, Hamp-
shire, UK). Before measuring, mice were anesthetized
with a combination of 6.25mg/kg acepromazine (Alfasan,
Woerden, The Netherlands), 6.25mg/kg midazolam (Roche,Experimental Diabetes Research 3
Mijdrecht, The Netherlands) and 0.3125mg/kg fentanyl
(Janssen-Cilag, Tilburg, The Netherlands).
2.5. Hyperinsulinemic Euglycemic Clamp. Prior to the exper-
iment, mice were fasted for 16 hours after food withdrawal
at 5:00 pm. Hyperinsulinemic euglycemic clamp studies
started at 9:00 am and were performed as described ear-
lier [26]. During the experiment, mice were anesthetized
with a combination of 6.25mg/kg acepromazine (Alfasan,
Woerden, The Netherlands), 6.25mg/kg midazolam (Roche,
Mijdrecht, The Netherlands) and 0.3125mg/kg fentanyl
(Janssen-Cilag, Tilburg, The Netherlands). First, basal rate
of glycerol turnover was determined by giving a primed
(0.6μCi) continuous (0.9μCi/h) intravenous (i.v.) infusion
of [1-(3)-3H]-Glycerol (GE Healthcare, Little Chalfont, UK)
for 60 minutes. Subsequently, insulin (Novo Nordisk, Den-
mark) was administered in a primed (4.5mU) continuous
(6.8mU/h)i.v.infusion for90minutestoattainasteadystate
circulating insulin concentration of ∼6μg/L.
Every 10min the plasma glucose concentration was
determined via tail vein bleeding (<3μl) (Accu-chek, Sensor
Comfort, Roche Diagnostics GmbH, Mannheim, Germany)
and accordingly the i.v. infusion rate of a 12.5% D-glucose
solutionwasadjustedtomaintain euglycemia.Bloodsamples
(60μL) were taken during the basal period (at 50 and
60min) and during the hyperinsulinemic period (at 70, 80,
and 90min) to determine plasma concentrations of glucose,
insulin, nonesteriﬁed fatty acids (NEFA), free glycerol, and
3H-Glycerol speciﬁc activities. At the end of the clamp, mice
were sacriﬁced.
2.6. Analytical Procedures. Commercially available kits were
used to determine the plasma concentration of glucose
(Instruchemie, Delfzijl, The Netherlands), NEFA (Wako,
Nuess, Germany), and free glycerol (Sigma, MO, USA).
The plasma insulin concentration was measured by an
ELISA (Mercodia AB, Uppsala, Sweden). Total plasma 3H-
Glycerol was determined in plasma and in supernatant after
trichloroacetic acid (20%) precipitation and water evap-
oration.
2.7. Calculations. T h et u r n o v e rr a t eo fg l y c e r o l( μmol/
min/kg) was calculated during the basal period and under
steady-state hyperinsulinemic conditions as the rate of
tracer infusion (dpm/min) divided by the plasma-speciﬁc
activity of 3H-Glycerol(dpm/μmol).The turnoverrates were
corrected for body weight.
2.8. Statistical Analysis. Data is presented as mean ± stan-
dard deviation. Statistical analysis was performed using
SPSS. A one-way ANOVA was used for analysis of the data.
If signiﬁcant diﬀerences were found, the LSD method was
applied as posthoc test to determine diﬀerences between
2 groups. Statistical diﬀerences were only shown when
apparent between DIO and DR placebo groups, between
DIO placebo and bromocriptine groups, or between DR
placeboand haloperidolgroups. Diﬀerenceswere considered
statistically signiﬁcant when P<. 05.
3.Results
3.1. Body Weight and Basal Plasma Metabolites. Mice were
designated DIO or DR according to their weight gain
following a 10-week high fat diet. By deﬁnition, DIO mice
had a signiﬁcantly higher bodyweight compared to DR mice
after this dietary pretreatment (35.4 ± 1.5v e r s u s3 0 .6 ±
1.9; P<. 001), which was completely accounted for by a
diﬀerence in fat mass (Figure 1(b)). Lean body mass did
not diﬀer (not shown). Two weeks of placebo treatment did
not alter the diﬀerence in bodyweight between DIO and DR
mice (Figure 1(a)). Two weeks of bromocriptine treatment
tendedtoinduceweightlossinDIOmice(primarilyfatmass,
Figure 1(b)), although the eﬀe c td i dn o tr e a c hs t a t i s t i c a l
signiﬁcance. Haloperidol did not impact on the bodyweight
of DR mice.
The fasting plasma glucose concentration was not diﬀer-
ent between placebo treated DIOand DR mice (Figure 2(a)),
whereas the fasting plasma insulin concentration was sig-
niﬁcantly elevated in DIO mice (Figure 2(b)). Haloperidol
signiﬁcantly increased fasting plasma glucose and insulin
concentrations in DR mice, while the insulin and glucose
concentrations in DIO mice remained unchanged upon
bromocriptine treatment. The fasting plasma NEFA concen-
tration did not diﬀer between the groups (Figure 2(c)).
3.2. Energy Metabolism. After 1 week of treatment, whole
body energy metabolism of mice was assessed with a Com-
prehensive Laboratory Animal Monitoring System using
indirect calorimetry. Individualfoodintake,activity, andres-
piratory gas exchange was monitored for 3 consecutive days.
Cumulative food intake (Figure 3(a)), voluntary activity
(Figures 3(b) and 3(c)), energy expenditure (Figure 3(d))a s
well as the carbohydrate oxidation rate (data not shown) did
not diﬀer between placebo treated DIO and DR mice. The
diurnal fat oxidation rate tended to be higher in DIO mice,
but this failed to reach statistical signiﬁcance (Figure 3(e)).
Diurnal and nocturnal voluntary activity in DR mice was
dramatically reduced by haloperidol (Figures 3(b) and 3(c)),
and this was accompanied by a reduction in whole body
nocturnal energy expenditure (Figure 3(d)). The impact of
haloperidol on fat (Figure 3(e)) and carbohydrate oxidation
(data not shown) did not reach statistical signiﬁcance.
Food intake was not aﬀected by haloperidol treatment (Fig-
ure 3(a)). The diurnal voluntary activity tended to be lower
in DIO mice receiving bromocriptine, but this also failed
to reach statistical signiﬁcance (Figure 3(c)). Furthermore,
bromocriptine treatment had no signiﬁcant eﬀect on food
intake (Figure 3(a)), energy expenditure (Figure 3(d)), fat
oxidation (Figure 3(e)), or carbohydrate oxidation rate (data
not shown).
3.3. Insulin Action. After 2 weeks of treatment, mice were
subjected to a hyperinsulinemic euglycemicclamp.Basal and
hyperinsulinemic plasma glucose, insulin, free glycerol, and
NEFA concentrations are shown in Table 1.T h ep l a s m a
NEFA concentration was reduced to the same extent in all
groups during hyperinsulinemia.4 Experimental Diabetes Research
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Figure 1: Bodyweight (a) and fat mass (b) of DIO and DR mice after treatment with bromocriptine (BC), haloperidol (HP), or placebo (P)
for 2 weeks. Data is presented as mean ± SD for 12 (a) or 10 (b) mice per group. ∗∗P<. 01 ∗∗∗P<. 001.
Table 1: Plasma glucose, insulin, free glycerol, and NEFA concentrations during the basal and hyperinsulinemic conditions of the
hyperinsulinemic euglycemic clamp in DIO and DR mice after treatment with bromocriptine, haloperidol, or placebo for 2 weeks.
Clamp condition DIO mice DR mice
Placebo Bromocriptine Placebo Haloperidol
Glucose (mM) Basal 5.9 ±0.65 .3 ±1.15 .0 ±0.66 .7 ±1.7
Hyperinsulinemia 5.4 ±0.75 .6 ±0.66 .0 ±0.74 .8 ±1.1
Insulin (μg/L) Basal 2.4 ±0.32 .0 ±0.81 .6 ±0.52 .6 ±0.7
Hyperinsulinemia 6.8 ±1.97 .2 ±1.46 .7 ±1.37 .1 ±0.6
Free glycerol (mM) Basal 0.1 ±0.10 .1 ±0.10 .2 ±0.10 .2 ±0.1
Hyperinsulinemia 0.1 ±0.00 .1 ±0.00 .1 ±0.00 .1 ±0.0
NEFA (mM) Basal 1.0 ±0.21 .1 ±0.31 .1 ±0.21 .0 ±0.3
Hyperinsulinemia 0.5 ±0.10 .5 ±0.10 .5 ±0.20 .5 ±0.1
Data is measured in 9 or 10 mice and presented as mean ± SD.
The glucose infusion rate necessary to maintain eug-
lycemia was signiﬁcantly higher in DR compared to DIO
mice (Figure 4), which indicates that DIO mice were insulin
resistant compared to DR animals. Haloperidol signiﬁcantly
diminished the glucose infusion rate in DR mice, reﬂecting
a deterioration of insulin action, whereas bromocriptine
tendedtoincreaseglucoseinfusionrequiredtomaintaineug-
lycemia in DIO mice (indicating improved insulin action).
The capacity of insulin to inhibit glycerol turnover was not
diﬀerent between DR and DIO mice, and it was not aﬀected
by either drug (data not shown).
4.Discussion
Theresultspresentedheredemonstratethatpharmacological
modulation of dopaminergic transmission by a DRD2 ago-
nist or antagonist can partly redirect the divergent metabolic
phenotypes of DIO and DR mice. In particular, blocking
dopaminergic transmission by means of haloperidol induces
insulin resistance of glucose metabolism in DR mice.
Conversely, activation of dopaminergic neurotransmission
by bromocriptine tended to ameliorate insulin resistance
in DIO animals. These data suggest that DRD2-mediated
neurotransmission is involved in the control of glucose and
insulin metabolism.
Although they have a genetically identical background,
individual C57Bl6 mice show distinct susceptibility to
develop obesity and insulin resistance when maintained on
a high fat diet. We classiﬁed mice as DIO or DR based on the
amount ofweightgained during10weeksofhigh fat feeding.
DIO mice were insulin resistant compared to DR mice, as
evidenced by higher fasting plasma insulin levels and lower
glucoseinfusionraterequiredtomaintain euglycemiaduring
insulin infusion. These ﬁndings are in accordance with other
rodent studies [19–21, 24, 27]. Remarkably, there was no
measurable diﬀerence in food intake, energy expenditure, or
voluntary physical activity in DIO compared to DR mice.
DIO mice have signiﬁcantly lower DRD2 expression
levels in certain brain areas compared to DR mice [23].Experimental Diabetes Research 5
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(c) Figure 2: Fasting plasma glucose (a), insulin (b), and NEFA (c) concentrations in DIO and DR mice after treatment with bromocriptine
(BC), haloperidol (HP), or placebo (P) for 2 weeks. Data is presented as mean ± SD for 9 or 10 mice per group. ∗P<. 05 ∗∗P<. 01.
Also, dopamine turnover is reduced in hypothalamic nuclei
of DIO rats even before the onset of obesity [24], and the
hypothalamusisintimately involvedin thecontrolofglucose
and lipid metabolism [28, 29]. Sincepharmacological activa-
tion of DRD2ameliorates insulin resistance, in various obese
animal models [17, 30], we hypothesized that modulation
of DRD2-mediated neurotransmission could reverse the
metabolic phenotypes of DIO and DR mice. In keeping
with this hypothesis, blocking DRD2by haloperidol induced
insulinresistance inDRmice,whereasactivationofDRD2by
bromocriptine tended to improve insulin sensitivity in DIO
mice. In concert, these data suggest that DRD2 activation
is involved in the control of glucose metabolism and that
reduced dopaminergic transmission via DRD2 contributes
to the metabolic phenotype (insulin resistance) of obese
animals. However, we cannot exclude the possibility that
the observed eﬀects of bromocriptine and haloperidol are
(partly) mediated by receptors other than DRD2. Haloperi-
dol is also known to have a high aﬃnity for DRD3, DRD4
and adrenergic α1 receptors [31], and bromocriptine also
possesses high aﬃnity for DRD3, the serotonergic 5-HT1A
and 1D receptors, and the adrenergic α1a n dα2 receptors
[32]. Each of these receptors might participate in the impact
of haloperidol and/or bromocriptine on energy and nutrient
homeostasis. Adrenergic receptors (AR) are involved in
the control of energy expenditure and glucose metabolism.
Stimulation of α2-AR reduces spontaneous physical activity
[33] and impairs insulin secretion [34–36]. Accordingly,
overexpression of α2A-AR is associated with glucose intol-
erance [37]. Stimulation of α1-AR, on the other hand, has
a positive impact on glucose homeostasis by promoting
glucose uptake by adipose and muscle tissue [38–40]a n d
absence of theα1B-ARleadsto hyperinsulinemia and insulin
resistance [41]. Acute stimulation of the 5-HT1A receptor
increases food intake [42, 43], reduces plasma insulin levels
and induces a concomitant rise in plasma glucose levels
[44, 45] .A sf a ra sw ek n o w ,t h es p e c i ﬁ ci m p a c to fD R D 3 ,
DRD4, and 5-HT1D receptors on the regulation of energy
and nutrient homeostasis is still unknown. Thus, the eﬀects
of bromocriptine and haloperidol we observe here may be6 Experimental Diabetes Research
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Figure 3:Cumulative foodintake(a),meannocturnal(b) anddiurnalx-axis activity (c),mean nocturnal energy expenditure (d), andmean
diurnal fat oxidation rate (e) in DIO and DR mice after treatment with bromocriptine (BC), haloperidol (HP), or placebo (P) for 1 week.
Data is presented as mean ± SD for 7 or 8 mice per group. ∗∗P<. 01; ∗∗∗P<. 001.Experimental Diabetes Research 7
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Figure 4: Glucose infusion rate during a hyperinsulinemic
euglycemic clamp in DIO and DR mice after treatment with
bromocriptine (BC), haloperidol (HP), or placebo (P) for 2 weeks.
Data is presented as mean ± SD for 9 or 10 mice per group. ∗P<
.05; ∗∗∗P<. 001.
theultimate result ofmodulationofvarious ofthesereceptor
activities.
The fact that haloperidol induced insulin resistance is
consistent with literature reporting an increased incidence
of diabetes among individuals treated with haloperidol [46].
Interestingly, treatment with haloperidol is not associated
with (massive) weight gain in humans [47], which also
ﬁts with our data and suggests that the drug hampers
insulin action via mechanistic routes other than obesity.
First, haloperidol dramatically reduced physical activity of
DR mice. This is in agreement with a wealth of data from
other animal experiments [48, 49]. Diminished locomotor
activity hampers insulin action in muscle [50, 51]. Second,
am a j o r( s i d e )e ﬀect of haloperidol treatment is elevation
of prolactin levels [52, 53] which may contribute to the
induction of glucose intolerance and insulin resistance [54,
55]. Third, haloperidol may alter glucose metabolism by
modifying plasma levels of peptide hormones. The data
documenting eﬀects of haloperidol on leptin levels are
inconsistent;increased [56]aswell asunchangedleptinlevels
in response to haloperidol treatment have been reported
[57, 58]. Furthermore, haloperidol seems to increase plasma
ghrelin levels, while leaving levels of adiponectin, resistin,
and visfatin unaﬀected [56]. Both leptin and ghrelin may
impact insulin sensitivity directly [59, 60]. Fourth, haloperi-
dol may diminish glucose-induced insulin secretion by
blocking D2 receptors on pancreatic β-cells [61, 62], which
leads to (postprandial) hyperglycemia. In the long run,
hyperglycemia diminishes insulin action through “toxic”
eﬀects on insulin sensitive tissues [63]. Fifth, blockade of
central DRD2 may induce insulin resistance via modulation
ofautonomicnervousoutputtoperipheraltissues(including
muscle, adipose tissue, and liver) [64].
Bromocriptine treatment tended to improve insulin
sensitivity of glucose metabolism in DIO animals, but its
eﬀect on glucose infusion rate did not reach statistical
signiﬁcance. It is important to note that the route of
administration of bromocriptine we used here may have
diminished the eﬃcacy of the drug. Indeed, it has been
shown that subcutaneous, compared to intraperitoneal,
administration of the drug limits its metabolic impact
[65] .T h et e n d e n c yw eo b s e r v e dt h o u g hi si nl i n ew i t h
data obtained in diet induced obese hamsters [66], and
geneticallyengineered obese mice[67]. In accordance, short-
term administration of bromocriptine ameliorates various
metabolicanomaliesinobesehumanswithoutaﬀectingbody
weight [18] and longer term treatment improves glycemic
control and serum lipid proﬁles in patients with type 2
diabetes [68]. In addition, DRD2 agonists improve glucose
and lipid metabolism in patients with hyperprolactinemia
[69, 70]a n da c r o m e g a l y[ 71–73]. Although DRD2 agonists
generally beneﬁt nutrient metabolism, the use of these drugs
is sometimes associated with the development of impulse
control disorders, including binge and compulsive eating, in
patientswithParkinson’s disease,which mayleadtoexcessive
weight gain and insulin resistance [74, 75].
The eﬀects of bromocriptine on metabolism may be
mediated by central dopamine receptors, as is suggested
by Luo et al. [17] who showed that intracerebroventricular
administration of low dose bromocriptine during 14 days
improves insulin sensitivity in obese, insulin-resistant, ham-
sters. However, peripheral receptors might also be involved.
We previously reported that bromocriptine acutely impairs
insulin secretion bystimulating theα2-ARonβ-cells[36].To
explainthat(sub)chronicbromocriptinetreatmentimproves
glucose metabolism [15, 66, 76], we hypothesized that
suppression of insulin secretion induces β-cell “rest”, which
might allow β-cells to replenish insulin stores, thereby
enhancing the secretory capacity in the long run [77, 78].
It might also increase the number of organ-speciﬁc insulin
receptors leading to improved insulin sensitivity [79, 80]. In
addition, bromocriptine may alter glucose metabolism via
modulation of circulating peptide levels. In obese women,
bromocriptine reduces leptin concentrations [81]; the bio-
logical relevance of this for the results reported by us is
questionable however, as leptin improves insulin sensitivity
[59]. The impact of bromocriptine on other regulatory
peptide hormones remains to be determined.
In summary, activation of DRD2 tends to ameliorate
the metabolic proﬁle of DIO mice, whereas antagonism of
these receptors induces insulin resistance in DR mice. In
concert with previous ﬁndings by other groups indicating
that dopaminergic (DRD2 mediated) neurotransmission is
reduced in the brain of DIO mice, our data suggest that
DRD2-mediateddopaminergicmechanisms maybeinvolved
in the developmentofthedivergentmetabolic phenotypesin
response to high fat feeding in C57Bl6 mice.
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